| Histone methylation status of H3K4me3 and H3K9me3 under methionine restriction is unstable in methionine-addicted cancer cells, but stable in normal cells J Yamamoto, Q Han, S Inubushi, N Sugisawa, K Hamada, H Nishino, ... Biochemical and biophysical research communications 533 (4), 1034-1038, 2020 | 70 | 2020 |
| The combination of oral-recombinant methioninase and azacitidine arrests a chemotherapy-resistant osteosarcoma patient-derived orthotopic xenograft mouse model T Higuchi, N Sugisawa, J Yamamoto, H Oshiro, Q Han, N Yamamoto, ... Cancer Chemotherapy and Pharmacology 85, 285-291, 2020 | 42 | 2020 |
| Extent and instability of trimethylation of histone H3 lysine increases with degree of malignancy and methionine addiction J Yamamoto, Y Aoki, S Inubushi, Q Han, K Hamada, Y Tashiro, K Miyake, ... Cancer Genomics & Proteomics 19 (1), 12-18, 2022 | 40 | 2022 |
| Oral recombinant methioninase increases TRAIL receptor-2 expression to regress pancreatic cancer in combination with agonist tigatuzumab in an orthotopic mouse model J Yamamoto, K Miyake, Q Han, Y Tan, S Inubushi, N Sugisawa, T Higuchi, ... Cancer Letters 492, 174-184, 2020 | 38 | 2020 |
| Linkage of methionine addiction, histone lysine hypermethylation, and malignancy J Yamamoto, S Inubushi, Q Han, Y Tashiro, N Sugisawa, K Hamada, ... Iscience 25 (4), 2022 | 36 | 2022 |
| Efficacy of oral recombinant methioninase combined with oxaliplatinum and 5-fluorouracil on primary colon cancer in a patient-derived orthotopic xenograft mouse model JH Park, M Zhao, Q Han, Y Sun, T Higuchi, N Sugisawa, J Yamamoto, ... Biochemical and biophysical research communications 518 (2), 306-310, 2019 | 36 | 2019 |
| Pure laparoscopic right posterior sectionectomy using the caudate lobe-first approach Y Homma, G Honda, M Kurata, Y Ome, M Doi, J Yamamoto Surgical Endoscopy 33, 3851-3857, 2019 | 33 | 2019 |
| Reversion of methionine addiction of osteosarcoma cells to methionine independence results in loss of malignancy, modulation of the epithelial-mesenchymal phenotype and … Y Aoki, Q Han, Y Tome, J Yamamoto, Y Kubota, N Masaki, K Obara, ... Frontiers in Oncology 12, 1009548, 2022 | 31 | 2022 |
| Stage IV pancreatic cancer patient treated with FOLFIRINOX combined with oral methioninase: a highly-rare case with long-term stable disease Y Kubota, Q Han, C Hozumi, N Masaki, J Yamamoto, Y Aoki, T Tsunoda, ... Anticancer Research 42 (5), 2567-2572, 2022 | 30 | 2022 |
| PPARγ agonist pioglitazone in combination with cisplatinum arrests a chemotherapy-resistant osteosarcoma PDOX model T Higuchi, J Yamamoto, N Sugisawa, Y Tashiro, H Nishino, N Yamamoto, ... Cancer Genomics & Proteomics 17 (1), 35-40, 2020 | 26 | 2020 |
| Methionine restriction: ready for prime time in the cancer clinic? JUN Yamamoto, Q Han, M Simon, D Thomas, RM Hoffman Anticancer Research 42 (2), 641-644, 2022 | 24 | 2022 |
| Oral-recombinant methioninase converts an osteosarcoma from docetaxel-resistant to-sensitive in a clinically-relevant patient-derived orthotopic-xenograft (PDOX) mouse model Y Aoki, Y Tome, NF Wu, J Yamamoto, K Hamada, Q Han, M Bouvet, ... Anticancer Research 41 (4), 1745-1751, 2021 | 24 | 2021 |
| Reversion from methionine addiction to methionine independence results in loss of tumorigenic potential of highly-malignant lung-cancer cells J Yamamoto, Y Aoki, Q Han, N Sugisawa, YU Sun, K Hamada, H Nishino, ... Anticancer Research 41 (2), 641-643, 2021 | 24 | 2021 |
| Efficacy of oral recombinant methioninase and eribulin on a PDOX model of triple-negative breast cancer (TNBC) liver metastasis HI Lim, YU Sun, Q Han, J Yamamoto, RM Hoffman in vivo 35 (5), 2531-2534, 2021 | 23 | 2021 |
| Oral recombinant methioninase combined with oxaliplatinum and 5-fluorouracil regressed a colon cancer growing on the peritoneal surface in a patient-derived orthotopic … JH Park, Q Han, M Zhao, Y Tan, T Higuchi, SN Yoon, N Sugisawa, ... Tissue and Cell 61, 109-114, 2019 | 22 | 2019 |
| Triple-methyl blockade with recombinant methioninase, cycloleucine, and azacitidine arrests a pancreatic cancer patient-derived orthotopic xenograft model N Sugisawa, J Yamamoto, Q Han, Y Tan, Y Tashiro, H Nishino, ... Pancreas 50 (1), 93-98, 2021 | 20 | 2021 |
| Oral methioninase inhibits recurrence in a PDOX mouse model of aggressive triple-negative breast cancer HI Lim, K Hamada, J Yamamoto, Q Han, Y Tan, HJ Choi, SJ Nam, ... in vivo 34 (5), 2281-2286, 2020 | 20 | 2020 |
| Oral recombinant methioninase prevents obesity in mice on a high-fat diet Y Tashiro, Q Han, Y Tan, N Sugisawa, J Yamamoto, H Nishino, ... in vivo 34 (2), 489-494, 2020 | 20 | 2020 |
| Oral recombinant methioninase combined with paclitaxel arrests recalcitrant ovarian clear cell carcinoma growth in a patient-derived orthotopic xenograft (PDOX) nude-mouse model N Sugisawa, T Higuchi, Q Han, C Hozumi, J Yamamoto, Y Tashiro, ... Cancer Chemotherapy and Pharmacology 88, 61-67, 2021 | 19 | 2021 |
| Combination methionine-methylation-axis blockade: a novel approach to target the methionine addiction of cancer T Higuchi, Q Han, N Sugisawa, J Yamamoto, N Yamamoto, K Hayashi, ... Cancer Genomics & Proteomics 18 (2), 113-120, 2021 | 19 | 2021 |
Robert M HoffmanAntiCancer, Inc.Verified email at anticancer.com
